Understanding the immunogenicity and antigenicity of nanomaterials: Past, present and future

Toxicology and Applied Pharmacology

Volumn 299, Issue , 2016, Pages 70-77

  Ilinskaya, Anna N ^a   Dobrovolskaia, Marina A ^a  

^a FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

Anaphylaxis; Antibody; Antigenicity; Cytokines; Immunogenicity; Nanoparticles; Phagocytosis; Preclinical

Indexed keywords

NANOCARRIER; NANOCOATING; NANOMATERIAL; RECOMBINANT PROTEIN; DRUG CARRIER; IMMUNOLOGICAL ADJUVANT;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGENICITY; ARTICLE; CLINICAL RESEARCH; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; NANOENGINEERING; NONHUMAN; PHAGOCYTOSIS; ADVERSE EFFECTS; ANIMAL; ANTIGENIC MODULATION; CELLULAR IMMUNITY; COMPREHENSION; DRUG DELIVERY SYSTEM; DRUG EFFECTS; FORECASTING; IMMUNOGENETICS; IMMUNOLOGY; PROCEDURES;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENIC MODULATION; COMPREHENSION; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FORECASTING; HUMANS; IMMUNITY, CELLULAR; IMMUNOGENETIC PHENOMENA; NANOSTRUCTURES;

EID: 84954348497     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2016.01.005     Document Type: Article

References (113)

1. Abu Lila A.S., Kiwada H., Ishida T. The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage. J. Control. Release 2013, 172:38-47.
2. Abuchowski A., McCoy J.R., Palczuk N.C., van Es T., Davis F.F. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J. Biol. Chem. 1977, 252:3582-3586.
3. Abuchowski A., van Es T., Palczuk N.C., Davis F.F. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J. Biol. Chem. 1977, 252:3578-3581.
4. Agashe H.B., Dutta T., Garg M., Jain N.K. Investigations on the toxicological profile of functionalized fifth-generation poly (propylene imine) dendrimer. J. Pharm. Pharmacol. 2006, 58:1491-1498.
5. Aggarwal P., Hall J.B., McLeland C.B., Dobrovolskaia M.A., McNeil S.E. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv. Drug Deliv. Rev. 2009, 61:428-437.
6. Alving C.R. Natural antibodies against phospholipids and liposomes in humans. Biochem. Soc. Trans. 1984, 12:342-344.
7. Alving C.R. Antibodies to liposomes, phospholipids and phosphate esters. Chem. Phys. Lipids 1986, 40:303-314.
8. Alving C.R., Swartz G.M., Wassef N.M., Ribas J.L., Herderick E.E., Virmani R., Kolodgie F.D., Matyas G.R., Cornhill J.F. Immunization with cholesterol-rich liposomes induces anti-cholesterol antibodies and reduces diet-induced hypercholesterolemia and plaque formation. J. Lab. Clin. Med. 1996, 127:40-49.
9. Andreev S.M., Babakhin A.A., Petrukhina A.O., Romanova V.S., Parnes Z.N., Petrov R.V. Immunogenic and allergenic properties of fulleren conjugates with aminoacids and proteins. Dokl. Biochem. 2000, 370:261-264.
10. Andreev S.M., Babakhin A.A., Petrukhina A.O., Romanova V.S., Parnes Z.N., Petrov R.V. Immunogenic and allergenic properties of fulleren conjugates with aminoacids and proteins. Dokl. Biochem. 2000, 370:4-7.
11. Arima Y., Toda M., Iwata H. Complement activation on surfaces modified with ethylene glycol units. Biomaterials 2008, 29:551-560.
12. Armstrong J.K., Hempel G., Koling S., Chan L.S., Fisher T., Meiselman H.J., Garratty G. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 2007, 110:103-111.
13. Artzy Schnirman A., Zahavi E., Yeger H., Rosenfeld R., Benhar I., Reiter Y., Sivan U. Antibody molecules discriminate between crystalline facets of a gallium arsenide semiconductor. Nano Lett. 2006, 6:1870-1874.
14. Bachmann M.F., Rohrer U.H., Kundig T.M., Burki K., Hengartner H., Zinkernagel R.M. The influence of antigen organization on B cell responsiveness. Science 1993, 262:1448-1451.
15. Banerji B., Kenny J.J., Scher I., Alving C.R. Antibodies against liposomes in normal and immune-defective mice. J. Immunol. 1982, 128:1603-1607.
16. Barbas C.F., Rosenblum J.S., Lerner R.A. Direct selection of antibodies that coordinate metals from semisynthetic combinatorial libraries. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:6385-6389.
17. Bee J.S., Chiu D., Sawicki S., Stevenson J.L., Chatterjee K., Freund E., Carpenter J.F., Randolph T.W. Monoclonal antibody interactions with micro- and nanoparticles: adsorption, aggregation, and accelerated stress studies. J. Pharm. Sci. 2009, 98:3218-3238.
18. Braden B.C., Goldbaum F.A., Chen B.X., Kirschner A.N., Wilson S.R., Erlanger B.F. X-ray crystal structure of an anti-Buckminsterfullerene antibody fab fragment: biomolecular recognition of C(60). Proc. Natl. Acad. Sci. U. S. A. 2000, 97:12193-12197.
19. Buttel I.C., Chamberlain P., Chowers Y., Ehmann F., Greinacher A., Jefferis R., Kramer D., Kropshofer H., Lloyd P., Lubiniecki A., Krause R., Mire-Sluis A., Platts-Mills T., Ragheb J.A., Reipert B.M., Schellekens H., Seitz R., Stas P., Subramanyam M., Thorpe R., Trouvin J.H., Weise M., Windisch J., Schneider C.K. Taking immunogenicity assessment of therapeutic proteins to the next level. Biologicals 2011, 39:100-109.
20. Carpenter J.F., Randolph T.W., Jiskoot W., Crommelin D.J., Middaugh C.R., Winter G., Fan Y.X., Kirshner S., Verthelyi D., Kozlowski S., Clouse K.A., Swann P.G., Rosenberg A., Cherney B. Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. J. Pharm. Sci. 2009, 98:1201-1205.
21. Carpenter J., Cherney B., Lubinecki A., Ma S., Marszal E., Mire-Sluis A., Nikolai T., Novak J., Ragheb J., Simak J. Meeting report on protein particles and immunogenicity of therapeutic proteins: filling in the gaps in risk evaluation and mitigation. Biologicals 2010, 38:602-611.
22. Chamberlain P., Mire-Sluis A.R. An overview of scientific and regulatory issues for the immunogenicity of biological products. Dev. Biol. (Basel) 2003, 112:3-11.
23. Charrois G.J., Allen T.M. Multiple injections of pegylated liposomal Doxorubicin: pharmacokinetics and therapeutic activity. J. Pharmacol. Exp. Ther. 2003, 306:1058-1067.
24. Chen B.X., Wilson S.R., Das M., Coughlin D.J., Erlanger B.F. Antigenicity of fullerenes: antibodies specific for fullerenes and their characteristics. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:10809-10813.
25. Cheng T.L., Wu P.Y., Wu M.F., Chern J.W., Roffler S.R. Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM. Bioconjug. Chem. 1999, 10:520-528.
26. Chi E.Y., Weickmann J., Carpenter J.F., Manning M.C., Randolph T.W. Heterogeneous nucleation-controlled particulate formation of recombinant human platelet-activating factor acetylhydrolase in pharmaceutical formulation. J. Pharm. Sci. 2005, 94:256-274.
27. Cui J., Li C., Wang C., Li Y., Zhang L., Yang H. Repeated injection of pegylated liposomal antitumour drugs induces the disappearance of the rapid distribution phase. J. Pharm. Pharmacol. 2008, 60:1651-1657.
28. Dams E.T., Laverman P., Oyen W.J., Storm G., Scherphof G.L., van Der Meer J.W., Corstens F.H., Boerman O.C. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J. Pharmacol. Exp. Ther. 2000, 292:1071-1079.
29. De Groot A.S., Scott D.W. Immunogenicity of protein therapeutics. Trends Immunol. 2007, 28:482-490.
30. Dobrovolskaia M.A. Nanoparticles and antigenicity. Handbook of Immunological Properties of Engineered Nanomaterilas 2013, 547-580. World Scientific Publishing Co. Pte. Ltd, Singapore. M.A. Dobrovolskaia, S.E. McNeil (Eds.).
31. Dobrovolskaia M.A., McNeil S.E. Immunological properties of engineered nanomaterials. Nat. Nanotechnol. 2007, 2:469-478.
32. Dobrovolskaia M.A., Aggarwal P., Hall J.B., McNeil S.E. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol. Pharm. 2008, 5:487-495.
33. Dykman L.A., Sumaroka M.V., Staroverov S.A., Zaitseva I.S., Bogatyrev V.A. Immunogenic properties of the colloidal gold. Izv. Akad. Nauk Ser. Biol. 2004, 86-91.
34. Eggebeen A.T. Gout: an update. Am. Fam. Physician 2007, 76:801-808.
35. Ennis R.D., Pritchard R., Nakamura C., Coulon M., Yang T., Visor G.C., Lee W.A. Glass vials for small volume parenterals: influence of drug and manufacturing processes on glass delamination. Pharm. Dev. Technol. 2001, 6:393-405.
36. Erlanger B.F., Chen B.X., Zhu M., Brus L. Binding of an anti-fullerene IgG monoclonal antibody to single wall carbon nanotubes. Nano Lett. 2001, 1:465-467.
37. Fifis T., Gamvrellis A., Crimeen-Irwin B., Pietersz G.A., Li J., Mottram P.L., McKenzie I.F., Plebanski M. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J. Immunol. 2004, 173:3148-3154.
38. Fradkin A.H., Carpenter J.F., Randolph T.W. Glass particles as an adjuvant: a model for adverse immunogenicity of therapeutic proteins. J. Pharm. Sci. 2011, 100:4953-4964.
39. Garay R.P., El-Gewely R., Armstrong J.K., Garratty G., Richette P. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert. Opin. Drug Deliv. 2012, 9:1319-1323.
40. Gershon S.K., Luksenburg H., Cote T.R., Braun M.M. Pure red-cell aplasia and recombinant erythropoietin. N. Engl. J. Med. 2002, 346:1584-1586. author reply 1584-1586.
41. Hashimoto Y., Abu Lila A.S., Shimizu T., Ishida T., Kiwada H. B cell-intrinsic toll-like receptor 7 is responsible for the enhanced anti-PEG IgM production following injection of siRNA-containing PEGylated lipoplex in mice. J. Control. Release 2014, 184:1-8.
42. Hashimoto Y., Shimizu T., Mima Y., Abu Lila A.S., Ishida T., Kiwada H. Generation, characterization and in vivo biological activity of two distinct monoclonal anti-PEG IgMs. Toxicol. Appl. Pharmacol. 2014, 277:30-38.
43. Hashimoto Y., Shimizu T., Abu Lila A.S., Ishida T., Kiwada H. Relationship between the concentration of anti-polyethylene glycol (PEG) immunoglobulin M (IgM) and the intensity of the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes in mice. Biol. Pharm. Bull. 2015, 38:417-424.
44. Hendrickson O., Fedyunina N., Zherdev A., Solopova O., Sveshnikov P., Dzantiev B. Production of monoclonal antibodies against fullerene C60 and development of a fullerene enzyme immunoassay. Analyst 2012, 137:98-105.
45. Hermeling S., Schellekens H., Crommelin D.J., Jiskoot W. Micelle-associated protein in epoetin formulations: a risk factor for immunogenicity?. Pharm. Res. 2003, 20:1903-1907.
46. Hermeling S., Crommelin D.J., Schellekens H., Jiskoot W. Structure-immunogenicity relationships of therapeutic proteins. Pharm. Res. 2004, 21:897-903.
47. Ichihara M., Shimizu T., Imoto A., Hashiguchi Y., Uehara Y., Ishida T., Kiwada H. Anti-PEG IgM response against PEGylated liposomes in mice and rats. Pharmaceutics 2011, 3:1-11.
48. Ishida T., Kiwada H. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int. J. Pharm. 2008, 354:56-62.
49. Ishida T., Ichikawa T., Ichihara M., Sadzuka Y., Kiwada H. Effect of the physicochemical properties of initially injected liposomes on the clearance of subsequently injected PEGylated liposomes in mice. J. Control. Release 2004, 95:403-412.
50. Ishida T., Harada M., Wang X.Y., Ichihara M., Irimura K., Kiwada H. Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes. J. Control. Release 2005, 105:305-317.
51. Ishida T., Atobe K., Wang X., Kiwada H. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection. J. Control. Release 2006, 115:251-258.
52. Ishida T., Ichihara M., Wang X., Kiwada H. Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes. J. Control. Release 2006, 115:243-250.
53. Ishida T., Ichihara M., Wang X., Yamamoto K., Kimura J., Majima E., Kiwada H. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J. Control. Release 2006, 112:15-25.
54. Ishida T., Wang X., Shimizu T., Nawata K., Kiwada H. PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. J. Control. Release 2007, 122:349-355.
55. Ishida T., Kashima S., Kiwada H. The contribution of phagocytic activity of liver macrophages to the accelerated blood clearance (ABC) phenomenon of PEGylated liposomes in rats. J. Control. Release 2008, 126:162-165.
56. Ishihara T., Maeda T., Sakamoto H., Takasaki N., Shigyo M., Ishida T., Kiwada H., Mizushima Y., Mizushima T. Evasion of the accelerated blood clearance phenomenon by coating of nanoparticles with various hydrophilic polymers. Biomacromolecules 2010, 11:2700-2706.
57. Jiang Y., Nashed-Samuel Y., Li C., Liu W., Pollastrini J., Mallard D., Wen Z.Q., Fujimori K., Pallitto M., Donahue L., Chu G., Torraca G., Vance A., Mire-Sluis T., Freund E., Davis J., Narhi L. Tungsten-induced protein aggregation: solution behavior. J. Pharm. Sci. 2009, 98:4695-4710.
58. Jiskoot W., Randolph T.W., Volkin D.B., Middaugh C.R., Schoneich C., Winter G., Friess W., Crommelin D.J., Carpenter J.F. Protein instability and immunogenicity: roadblocks to clinical application of injectable protein delivery systems for sustained release. J. Pharm. Sci. 2012, 101:946-954.
59. Judge A., McClintock K., Phelps J.R., Maclachlan I. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol. Ther. 2006, 13:328-337.
60. Kaminskas L.M., McLeod V.M., Porter C.J., Boyd B.J. Differences in colloidal structure of PEGylated nanomaterials dictate the likelihood of accelerated blood clearance. J. Pharm. Sci. 2011, 100:5069-5077.
61. Klinge J., Ananyeva N.M., Hauser C.A., Saenko E.L. Hemophilia A-from basic science to clinical practice. Semin. Thromb. Hemost. 2002, 28:309-322.
62. Koide H., Asai T., Hatanaka K., Urakami T., Ishii T., Kenjo E., Nishihara M., Yokoyama M., Ishida T., Kiwada H., Oku N. Particle size-dependent triggering of accelerated blood clearance phenomenon. Int. J. Pharm. 2008, 362:197-200.
63. Koide H., Asai T., Hatanaka K., Akai S., Ishii T., Kenjo E., Ishida T., Kiwada H., Tsukada H., Oku N. T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes. Int. J. Pharm. 2010, 392:218-223.
64. Krayukhina E., Tsumoto K., Uchiyama S., Fukui K. Effects of syringe material and silicone oil lubrication on the stability of pharmaceutical proteins. J. Pharm. Sci. 2015, 104:527-535.
65. Kunamneni A., Abdelghani T.T., Ellaiah P. Streptokinase-the drug of choice for thrombolytic therapy. J. Thromb. Thrombolysis 2007, 23:9-23.
66. Leach J.K., O'Rear E.A., Patterson E., Miao Y., Johnson A.E. Accelerated thrombolysis in a rabbit model of carotid artery thrombosis with liposome-encapsulated and microencapsulated streptokinase. Thromb. Haemost. 2003, 90:64-70.
67. Lee S.C., Parthasarathy R., Duffin T.D., Botwin K., Zobel J., Beck T., Lange G., Kunneman D., Janssen R., Rowold E., Voliva C.F. Recognition properties of antibodies to PAMAM dendrimers and their use in immune detection of dendrimers. Biomed. Microdevices 2001, 3:53-59.
68. Lee S.C., Parthasarathy R., Botwin K., Kunneman D., Rowold E., Lange G., Klover J., Abegg A., Zobel J., Beck T., Miller T., Hood W., Monahan J., McKearn J.P., Jansson R., Voliva C.F. Biochemical and immunological properties of cytokines conjugated to dendritic polymers. Biomed. Microdevices 2004, 6:191-202.
69. Leger R.M., Arndt P., Garratty G., Armstrong J.K., Meiselman H.J., Fisher T.C. Normal donor sera can contain antibodies to polyethylene glycol (PEG). Transfusion 2001, 41:29S.
70. Li C., Cao J., Wang Y., Zhao X., Deng C., Wei N., Yang J., Cui J. Accelerated blood clearance of pegylated liposomal topotecan: influence of polyethylene glycol grafting density and animal species. J. Pharm. Sci. 2012, 101:3864-3876.
71. Libutti S.K., Paciotti G.F., Byrnes A.A., Alexander H.R., Gannon W.E., Walker M., Seidel G.D., Yuldasheva N., Tamarkin L. Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin. Cancer Res. 2010, 16:6139-6149.
72. Liu W., Swift R., Torraca G., Nashed-Samuel Y., Wen Z.Q., Jiang Y., Vance A., Mire-Sluis A., Freund E., Davis J., Narhi L. Root cause analysis of tungsten-induced protein aggregation in pre-filled syringes. PDA J. Pharm. Sci. Technol. 2010, 64:11-19.
73. Liu L., Randolph T.W., Carpenter J.F. Particles shed from syringe filters and their effects on agitation-induced protein aggregation. J. Pharm. Sci. 2012, 101:2952-2959.
74. Macdougall I.C., Provenzano R., Sharma A., Spinowitz B.S., Schmidt R.J., Pergola P.E., Zabaneh R.I., Tong-Starksen S., Mayo M.R., Tang H., Polu K.R., Duliege A.M., Fishbane S. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. N. Engl. J. Med. 2013, 368:320-332.
75. Masalova O.V., Shepelev A.V., Atanadze S.N., Parnes Z.N., Romanova V.S., Vol'pina O.M., Semiletov Iu A., Kushch A.A. Immunostimulating effect of water-soluble fullerene derivatives-perspective adjuvants for a new generation of vaccine. Dokl. Akad. Nauk 1999, 369:411-413.
76. Mire-Sluis A., Cherney B., Madsen R., Polozova A., Rosenberg A., Smith H., Arora T., Narhi L. Analysis and immunogenic potential of aggregates and particles: a practical approach, part 2. BioProcess International 2011, 9:38-43.
77. Monopoli M.P., Walczyk D., Campbell A., Elia G., Lynch I., Bombelli F.B., Dawson K.A. Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. J. Am. Chem. Soc. 2011, 133:2525-2534.
78. Murphy K. Janeway's Immunobiology Garland Science 2012.
79. Nguyen P.D., O'Rear E.A., Johnson A.E., Lu R., Fung B.M. Thrombolysis using liposomal-encapsulated streptokinase: an in vitro study. Proc. Soc. Exp. Biol. Med. 1989, 192:261-269.
80. Nguyen P.D., O'Rear E.A., Johnson A.E., Patterson E., Whitsett T.L., Bhakta R. Accelerated thrombolysis and reperfusion in a canine model of myocardial infarction by liposomal encapsulation of streptokinase. Circ. Res. 1990, 66:875-878.
81. Owens D.E., Peppas N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 2006, 307:93-102.
82. Parenky A., Myler H., Amaravadi L., Bechtold-Peters K., Rosenberg A., Kirshner S., Quarmby V. New FDA draft guidance on immunogenicity. AAPS J. 2014, 16:499-503.
83. Perkins W.R., Vaughan D.E., Plavin S.R., Daley W.L., Rauch J., Lee L., Janoff A.S. Streptokinase entrapment in interdigitation-fusion liposomes improves thrombolysis in an experimental rabbit model. Thromb. Haemost. 1997, 77:1174-1178.
84. Ramani K., Miclea R.D., Purohit V.S., Mager D.E., Straubinger R.M., Balu-Iyer S.V. Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A. J. Pharm. Sci. 2008, 97:1386-1398.
85. Ramani K., Purohit V., Miclea R., Gaitonde P., Straubinger R.M., Balu-Iyer S.V. Passive transfer of polyethylene glycol to liposomal-recombinant human FVIII enhances its efficacy in a murine model for hemophilia A. J. Pharm. Sci. 2008, 97:3753-3764.
86. Reddy S.T., van der Vlies A.J., Simeoni E., Angeli V., Randolph G.J., O'Neil C.P., Lee L.K., Swartz M.A., Hubbell J.A. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat. Biotechnol. 2007, 25:1159-1164.
87. Richards R.L., Aronson J., Schoenbechler M., Diggs C.L., Alving C.R. Antibodies reactive with liposomal phospholipids are produced during experimental Trypanosoma rhodesiense infections in rabbits. J. Immunol. 1983, 130:1390-1394.
88. Richter A.W., Akerblom E. Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors. Int. Arch. Allergy Appl. Immunol. 1984, 74:36-39.
89. Roberts J.C., Bhalgat M.K., Zera R.T. Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst dendrimers. J. Biomed. Mater. Res. 1996, 30:53-65.
90. Rosenberg A.S. Immunogenicity of biological therapeutics: a hierarchy of concerns. Dev. Biol. (Basel) 2003, 112:15-21.
91. Saadati R., Dadashzadeh S., Abbasian Z., Soleimanjahi H. Accelerated blood clearance of PEGylated PLGA nanoparticles following repeated injections: effects of polymer dose, PEG coating, and encapsulated anticancer drug. Pharm. Res. 2013, 30:985-995.
92. Saifer M.G., Williams L.D., Sobczyk M.A., Michaels S.J., Sherman M.R. Selectivity of binding of PEGs and PEG-like oligomers to anti-PEG antibodies induced by methoxyPEG-proteins. Mol. Immunol. 2014, 57:236-246.
93. Sauerborn M., Brinks V., Jiskoot W., Schellekens H. Immunological mechanism underlying the immune response to recombinant human protein therapeutics. Trends Pharmacol. Sci. 2010, 31:53-59.
94. Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin. Ther. 2002, 24:1720-1740. discussion 1719.
95. Schellekens H., Hennink W.E., Brinks V. The immunogenicity of polyethylene glycol: facts and fiction. Pharm. Res. 2013, 30:1729-1734.
96. Schuster B.G., Neidig M., Alving B.M., Alving C.R. Production of antibodies against phosphocholine, phosphatidylcholine, sphingomyelin, and lipid A by injection of liposomes containing lipid A. J. Immunol. 1979, 122:900-905.
97. Seidl A., Hainzl O., Richter M., Fischer R., Bohm S., Deutel B., Hartinger M., Windisch J., Casadevall N., London G.M., Macdougall I. Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity. Pharm. Res. 2012, 29:1454-1467.
98. Semple S.C., Harasym T.O., Clow K.A., Ansell S.M., Klimuk S.K., Hope M.J. Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic acid. J. Pharmacol. Exp. Ther. 2005, 312:1020-1026.
99. Sherman M.R., Williams L.D., Sobczyk M.A., Michaels S.J., Saifer M.G. Role of the methoxy group in immune responses to mPEG-protein conjugates. Bioconjug. Chem. 2012, 23:485-499.
100. Shimizu T., Ishida T., Kiwada H. Transport of PEGylated liposomes from the splenic marginal zone to the follicle in the induction phase of the accelerated blood clearance phenomenon. Immunobiology 2013, 218:725-732.
101. Smith D.M., Simon J.K., Baker J.R. Applications of nanotechnology for immunology. Nat. Rev. Immunol. 2013, 13:592-605.
102. Swanson S.J. Immunogenicity issues in drug development. J. Immunotoxicol. 2006, 3:165-172.
103. Tagami T., Nakamura K., Shimizu T., Yamazaki N., Ishida T., Kiwada H. CpG motifs in pDNA-sequences increase anti-PEG IgM production induced by PEG-coated pDNA-lipoplexes. J. Control. Release 2010, 142:160-166.
104. Tatarewicz S.M., Mytych D.T., Manning M.S., Swanson S.J., Moxness M.S., Chirmule N. Strategic characterization of anti-drug antibody responses for the assessment of clinical relevance and impact. Bioanalysis 2014, 6:1509-1523.
105. Thirumangalathu R., Krishnan S., Ricci M.S., Brems D.N., Randolph T.W., Carpenter J.F. Silicone oil- and agitation-induced aggregation of a monoclonal antibody in aqueous solution. J. Pharm. Sci. 2009, 98:3167-3181.
106. Tsai N.M., Cheng T.L., Roffler S.R. Sensitive measurement of polyethylene glycol-modified proteins. Biotechniques 2001, 30:396-402.
107. Tyagi A.K., Randolph T.W., Dong A., Maloney K.M., Hitscherich C., Carpenter J.F. IgG particle formation during filling pump operation: a case study of heterogeneous nucleation on stainless steel nanoparticles. J. Pharm. Sci. 2009, 98:94-104.
108. Van Beers M.M., Gilli F., Schellekens H., Randolph T.W., Jiskoot W. Immunogenicity of recombinant human interferon beta interacting with particles of glass, metal, and polystyrene. J. Pharm. Sci. 2012, 101:187-199.
109. Verhoef J.J., Carpenter J.F., Anchordoquy T.J., Schellekens H. Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics. Drug Discov. Today 2014, 19:1945-1952.
110. Wang X., Ishida T., Kiwada H. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J. Control. Release 2007, 119:236-244.
111. Watanabe H., Nakanishi T., Umetsu M., Kumagai I. Human anti-gold antibodies: biofunctionalization of gold nanoparticles and surfaces with anti-gold antibodies. J. Biol. Chem. 2008, 283:36031-36038.
112. Xiang S.D., Selomulya C., Ho J., Apostolopoulos V., Plebanski M. Delivery of DNA vaccines: an overview on the use of biodegradable polymeric and magnetic nanoparticles. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2010, 2:205-218.
113. Zolnik B.S., Gonzalez-Fernandez A., Sadrieh N., Dobrovolskaia M.A. Nanoparticles and the immune system. Endocrinology 2010, 151:458-465.